Skip to main content

Table 2 Prediction accuracy of DR_SEQAN in comparison with other publicly available algorithms.

From: DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes

Inhibitor Total no. of isolates No. of drug-susceptible isolatesa Percentage of drug-susceptible isolates correctly predicted by the algorithms
    DR_SEQAN Retrogram ANRS HIVDB RegaInst
Zidovudine (AZT) 135 48 79.2 64.6 72.9 68.8 72.9
Zalcitabine (ddC) 130 106 83.0 18.9 n.d.b n.d. 24.5
Didanosine (ddI) 136 104 93.3 20.2 79.8 28.8 27.9
Lamivudine (3TC) 138 59 83.1 79.7 88.1 78.0 78.0
Stavudine (d4T) 136 85 60.0 38.8 41.2 37.6 67.1
Abacavir (ABC) 134 75 88.0 32.0 89.3 38.7 33.3
Nevirapine (NVP) 183 66 87.9 65.2 93.9 90.9 72.7
Delavirdine (DLV) 183 103 83.5 57.3 n.d. 82.5 58.3
Efavirenz (EFV) 180 97 79.4 48.5 67.0 64.9 49.5
Saquinavir (SQV) 548 278 65.8 73.4 89.9 73.4 80.9
Ritonavir (RTV) 510 237 67.9 75.1 84.0 88.6 77.2
Indinavir (IDV) 529 250 70.8 70.0 79.2 78.0 84.0
Nelfinavir (NFV) 567 224 66.1 70.5 80.4 73.7 77.7
Amprenavir (APV) 527 282 72.0 67.7 99.3 70.9 86.9
Lopinavir (LPV) 203 42 (99) 85.7 (43.4) 88.1 (60.6) 100 (87.9) 69.0 (29.3) 81.0 (45.5)
  1. a Drug susceptible isolates were defined as those that in comparison with the wild-type reference clone showed a fold-increase of the IC50 value for each drug, which was below 1.8-fold for AZT, 2.6-fold for ddC, 2-fold for ddI and d4T, 9-fold for 3TC, 4.5-fold for ABC, 6-fold for NVP, DLV and EFV, 1.7-fold for SQV and LPV, 2.5-fold for RTV and IDV, 3.6-fold for NFV and 2-fold for APV. Those cut-off values were consistent with those previously defined for the PhenoSense™ assay [24]. In the case of LPV, the values shown between parenthesis refer to the clinically relevant cut-off value of 10-fold [24].
  2. b n.d., not determined